Advertisement

Introduction

  • Carolina Witchmichen Penteado Schmidt
Chapter

Abstract

There is an important concept that professionals in oncology must have in mind when we talk about pharmacology in neonates and infants: In this book, as in most references about neonates and infants, the word “neonate” refers to a baby up to 28 days after birth [3]. If a neonate is born prematurely, he can still be called by this terminology—neonate—if he was born more than 28 days previously but his postmenstrual age is ≤42–46 weeks. A baby who was born more than 28 days previously is called an infant. A premature neonate is a baby who was born at <37 weeks of gestational age, and a term neonate is a baby who was born between 37 weeks and 41 weeks plus 6 days of gestational age. When an infant is more than 1 year old, he starts to be called a child. The postmenstrual age is the gestational age plus the postnatal age. The gestational age is the number of weeks from the first day of the mother’s last menstrual period until the baby’s birth, and the postnatal age is the time until birth [4] (Table 1.1).

References

  1. 3.
    US National Library of Medicine: Medline Plus. Medical encyclopedia. http://medlineplus.gov/encyclopedia.html. Accessed 29 Sept 2016.
  2. 4.
    Taketomo C, Hodding J, Kraus D. Pediatric & neonatal dosage handbook. 21st ed. Hudson: Lexicomp; 2014.Google Scholar
  3. 21.
    Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology: extensive interindividual variability despite limited size. J Pediatr Pharmacol Ther. 2011;16(3):170–84.PubMedPubMedCentralGoogle Scholar
  4. 47.
    McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic drugs agents in the very young child. Br J Cancer Suppl. 1992;18:S23–9.PubMedPubMedCentralGoogle Scholar
  5. 1.
    Schmidt CWP, Menezes FG. Drug therapy and interactions in pediatric oncology: a pocket guide. Switzerland: Springer; 2016.Google Scholar
  6. 43.
    Alamo L, Beck-Popovic M, Gudinchet F, Meuli R. Congenital tumors: imaging when life just begins. Insights Imaging. 2011;2(3):297–308.CrossRefGoogle Scholar
  7. 39.
    Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2015. www.cdc.gov/uscs.
  8. 40.
    Birch JM, Blair V. The epidemiology of infants cancers. Br J Suppl. 1992;18:S2–4.Google Scholar
  9. 41.
    Ibagy A, Silva DB, Seiben J, et al. Acute lymphoid leukemia in infants: 20 years of experience. J Pediatr. 2013;89(1):64–9.CrossRefGoogle Scholar
  10. 38.
    Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. Pediatric Cancer. http://ascopubs.org/doi/full/10.1200/jco.2005.09.095. Accessed 13 Jul 2017.
  11. 76.
    Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15:35–47.CrossRefGoogle Scholar
  12. 2.
  13. 65.
    Office of Statistics and Programming, National Center for Injury Prevention and Control, CDC: 10 leading causes of death by age group. United States 2010. https://www.cdc.gov/injury/wisqars/pdf/10LCID_All_Deaths_By_Age_Group_2010-a.pdf.
  14. 44.
    van der Linden MH, Creemers S, Pieters R. Diagnosis and management of neonatal leukaemia. Semin Fetal Neonatal Med. 2012;17(4):192–5.CrossRefGoogle Scholar
  15. 45.
    Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr. 2015;3:37.CrossRefGoogle Scholar
  16. 75.
    Glick RD, Hicks MJ, Nuchtern JG, et al. Renal tumors in infants less than 6 months of age. J Pediatr Surg. 2004;39(4):522–5.CrossRefGoogle Scholar
  17. 77.
    Kivelä TT, Hadjistilianou T. Neonatal retinoblastoma. Asia Pac J Ocol Nurs. 2017;4(3):197–204.CrossRefGoogle Scholar
  18. 72.
    Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. 2009;14(2):164–73.CrossRefGoogle Scholar
  19. 73.
    Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–13.CrossRefGoogle Scholar
  20. 74.
    Klusmann JH, Creutzig U, Zimmerman M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991–8.CrossRefGoogle Scholar
  21. 80.
    Fukuoka K, Yanagisawa T, Suzuki T, et al. Successful treatment of hemorrhagic congenital intracranial immature teratoma with neoadjuvant chemotherapy and surgery: case report. J Neurosurg Pediatr. 2014;13:38–41.CrossRefGoogle Scholar
  22. 81.
    Choudhury SR, Debnath PR, Pant N, Chowdhury L. Congenital immature teratoma of the retroperitoneum. J Neonatal Surg. 2013;2(3):33.PubMedPubMedCentralGoogle Scholar
  23. 78.
    Interiano RB, Davidoff AM. Current management of neonatal neuroblastoma. Curr Pediatr Rev. 2015;11(3):179–87.CrossRefGoogle Scholar
  24. 71.
    Veal GJ, Errington J, Hayden J, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51(14):2022–30.CrossRefGoogle Scholar
  25. 82.
    Schmidt LS, Schüz J, Lähteenmäki P, et al. Fetal growth, preterm birth, neonatal stress and risk for CNS tumors in children: a Nordic population- and register-based case-control study. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1042–52. http://cebp.aacrjournals.org/content/19/4/1042.CrossRefGoogle Scholar
  26. 83.
    Isaacs H Jr. Perinatal (fetal and neonatal) astrocytoma: a review. Childs Nerv Syst. 2016;32(11):2085–96.CrossRefGoogle Scholar
  27. 84.
    Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999;1(2):152–61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920752/pdf/11554387.pdf.CrossRefGoogle Scholar
  28. 42.
    Hunger SP, Loh KM, Baker KS, Schultz KR. Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia. Biol Blood Marrow Transplant. 2009;15(1):79–83.CrossRefGoogle Scholar
  29. 85.
    Powis M. Neonatal renal tumors. Early Hum Dev. 2010;86(10):607–12.CrossRefGoogle Scholar
  30. 86.
    Ritchey ML, Azizkhan RG, Beckwith JB, Hrabovsky EE, Haase GM. Neonatal Wilms tumor. J Pediatr Surg. 1995;30(6):856–9.CrossRefGoogle Scholar
  31. 79.
    McCahon E, Sorensen PH, Davis JH, Rogers PC, Schultz KR. Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol. 2003;40(5):288–92.CrossRefGoogle Scholar
  32. 87.
    Isaacs H Jr. Fetal and neonatal hepatic tumors. J Pediatr Surg. 2007;42(11):1797–803.CrossRefGoogle Scholar
  33. 88.
    Isaacs H Jr. Fetal and neonatal cardiac tumors. J Pediatr Cardiol. 2004;25(3):252–73.Google Scholar
  34. 89.
    Uzun O, Wilson DG, Vujanic GM, Parsons JM, De Giovanni JV. Cardiac tumours in children. Orphanet J Rare Dis. 2007;2(1):11.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Carolina Witchmichen Penteado Schmidt
    • 1
  1. 1.CuritibaBrazil

Personalised recommendations